Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.
775 F. Supp. 2d 985
E.D. Mich.2011Background
- Novo Nordisk sues Caraco for infringement of the '358 Patent (NIDDM Regimen) related to repaglinide/metformin therapy.
- Caraco challenges patent validity on anticipation and obviousness and unenforceability due to inequitable conduct and patent misuse.
- The court held a trial in 2010 addressing anticipation, obviousness, and inequitable conduct; the patent issued January 13, 2004.
- Claim 4 covers a method of treating NIDDM with repaglinide in combination with metformin.
- The court found the claim not anticipated, invalid as obvious, and unenforceable due to inequitable conduct.
- Key prosecution history involved Melander, Sturis, and attorney Bork, with reliance on Sturis' declaration before the Patent Office.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Anticipation of Claim 4 | Novo argues Rachman-type references anticipate by disclosing metformin+repaglinide. | Caraco asserts no single prior art teaches the exact metformin/repaglinide combo. | Not anticipated |
| Obviousness of Claim 4 | Novo contends prior art taught combining different mechanisms (metformin with secretagogues) with synergistic/added effects. | Caraco contends the combination would not have been obvious given uncertainties and art distinctions. | Obviousness shown |
| Inequitable Conduct | Novo argues no intent to deceive, and information was merely contested. | Caraco asserts Sturis and Bork withheld and misrepresented material data to the PTO. | Inequitable conduct found; patent unenforceable |
Key Cases Cited
- KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (U.S. 2007) (obviousness framework rejects rigid TSM; requires reason to combine)
- Pfizer Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007) (prima facie obviousness requires clear and convincing proof)
- Bayer Schering Pharma AG v. Barr Labs., Inc., 575 F.3d 1341 (Fed. Cir. 2009) (teaching, suggestion, motivation and obvious-to-try analyses)
- In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009) (articulates about obvious-to-try and finite identified solutions)